Form 4 for LLY Lilly (Eli)
Accepted 2022-02-11 00:00:00 ET · period of report 2022-02-09 · accession 0000059478-22-000044 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-11 | 2022-02-09 | LLY | Mason Michael B | SVP, Pres, Lilly Diabetes | A - Grant | $243.27 | +2,612 | 27.5K | +10% | +$635.4K |
| D | 2022-02-11 | 2022-02-09 | LLY | Mason Michael B | SVP, Pres, Lilly Diabetes | A - Grant | $0.00 | +6,690 | 6,690 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-09 | A | A | 2,612 | $243.27 | 27,506 | D | — | — | |
| 2 | Derivative | Restricted Stock Unit | 2022-02-09 | A | A | 6,690 | $0.00 | 6,690 | D | — · 2023-02-01 to 2023-02-01 | 6,690 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |